Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Shares Outstanding (Weighted Average) (2016 - 2025)

Karyopharm Therapeutics' Shares Outstanding (Weighted Average) history spans 13 years, with the latest figure at $10.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 176.36% year-over-year to $10.2 million; the TTM value through Dec 2025 reached $10.2 million, up 176.36%, while the annual FY2025 figure was $10.2 million, 176.36% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $10.2 million in Q4 2025 per KPTI's latest filing, up from $8669.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $114.0 million in Q3 2023 to a low of $7700.0 in Q1 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $44.7 million, with a median of $42.4 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 110088.24% in 2021, then tumbled 99.99% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $75.2 million in 2021, then tumbled by 99.89% to $81871.0 in 2022, then surged by 696.83% to $652370.0 in 2023, then surged by 467.79% to $3.7 million in 2024, then soared by 176.36% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Shares Outstanding (Weighted Average) are $10.2 million (Q4 2025), $8669.0 (Q3 2025), and $8545.0 (Q2 2025).